Exercícios para miopatia mitocondrial (MELAS/MERRF/KSS) — aeróbico gradual MELHORA OXPHOS (Taivassalo 2006) + CoQ10 + creatina

Pfeffer 2012 + Mancuso 2017 + Parikh 2015 + Murphy 2008 framework. Mitochondrial myopathies are a heterogeneous group of disorders caused by mutations in mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) affecting oxidative phosphorylation (OXPHOS) and ATP production. Because ATP is universally needed, the affected tissues are those with the highest metabolic demand: skeletal muscle, brain, heart, retina, hearing apparatus, and endocrine organs (especially β-cells → diabetes). Key syndromes include MELAS (mitochondrial encephalomyopathy + lactic acidosis + stroke-like episodes, m.3243A>G in MT-TL1 is most common), MERRF (myoclonic epilepsy + ragged-red fibers, m.8344A>G in MT-TK), Kearns-Sayre syndrome (progressive external ophthalmoplegia + pigmentary retinopathy + cardiac conduction block onset before age 20, large mtDNA deletions), Leber hereditary optic neuropathy (LHON, painless bilateral central vision loss in young men), Leigh syndrome (pediatric encephalopathy with basal ganglia + brainstem lesions), and chronic progressive external ophthalmoplegia (CPEO). Heteroplasmy (different ratios of mutated vs wild-type mtDNA across tissues) explains the wide phenotypic variability within a single mutation. Cardiac surveillance per subtype (KSS heart block — ICD threshold lower per Wahbi 2015; MELAS cardiomyopathy — annual echo + Holter), endocrine (diabetes 10-30%), hearing (audiometry baseline + serial), ophthalmology (retinopathy + ptosis + ophthalmoplegia + LHON). Exercise per Cejudo 2005 + Taivassalo 2006 + Tarnopolsky 2008: graded aerobic + light strength IS safe + IMPROVES OXPHOS capacity + reduces fatigue + may even shift heteroplasmy in some studies (mechanistic). AVOID exhaustion + AVOID statins (rhabdomyolysis risk) + AVOID valproate in KSS (hepatotoxicity).

Volya's catalogue carries the foundation moves: supported-glute-bridge for posterior chain low-intensity activation, wall-push-up for upper-body push at low load, scapular-retraction for upper-back posture, cat-cow for spinal mobility, supine-knee-to-chest for low-back release + hip flexor stretch, diaphragmatic-breathing as central respiratory training (KSS + MELAS respiratory involvement), pursed-lip-breathing for dyspnea + respiratory muscle endurance, seated-march for cardio without joint impact + low-energy cost option, sit-to-stand for functional + bone-loading within ability. The AI coach also knows the nutrition side — CoQ10 100-300 mg (Glover 2010 + Stacpoole 2012 modest benefit, ubiquinol better absorbed), CREATINE 5-10 g/day (Tarnopolsky 2008/2007 strongest evidence-based intervention in mito myopathy), L-CARNITINE 1-3 g if secondary deficiency (metabolic team), L-ARGININE 0.1-0.5 g/kg IV during MELAS stroke-like episode + 0.15-0.30 g/kg/day chronic oral (Koga 2007), Mediterranean base + AVOID prolonged fasts (energy crash + decompensation), protein 1.2-1.5 g/kg + leucine 2.5-3 g per meal, frequent small meals (avoid blood sugar drops), diabetes management (low-GI Mediterranean), Ca + vit D + DEXA, AVOID statins + valproate KSS + metformin in MELAS (lactic acidosis risk) + barbiturates/tetracyclines + alcohol excess + ultra-processed + long fasts + restrictive fad diets, consider alpha-lipoic acid + vit E + riboflavin + thiamine 'mito cocktail' (Parikh 2015). CRITICAL: United Mitochondrial Disease Foundation (UMDF) + MitoAction + Australian Mitochondrial Disease Foundation (AMDF) + MitoCanada + International Mito Patients + MDA + metabolic geneticist (mitochondrial-experienced) + cardiology + endocrinology + ophthalmology + audiology + neurology + dietitian + family genetic counselling (mtDNA maternal + heteroplasmy + nDNA AR/AD). This is NEVER a replacement for mitochondrial-experienced metabolic geneticist care.